If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
79
results.
Updated on
14/10/2025 [06:46:00]
Results 25 to 50 of 79
Absstract of: WO2025192800A1
The present invention relates to a pharmaceutical composition for preventing or treating Alzheimer's disease, the composition comprising, as an active ingredient, neural crest-derived nasal turbinate stem cells (NTSCs) expressing SSEA3 and CD105. Treatment with the NTSCs expressing SSEA3 and CD105 or with an NTSC cell line including at least a predetermined proportion of the NTSCs was found to result in remarkably good therapeutic activity against Alzheimer's disease. Therefore, the present invention is expected to be effectively used not only as a composition for preventing or treating Alzheimer's disease in which the composition includes, as an active ingredient, NTSCs expressing SSEA3 and CD105 or an NTSC cell line including at least a predetermined proportion of the NTSCs, but also for uses such as screening of NTSC formulations that can be used to treat Alzheimer's disease, or prediction of the therapeutic efficacy thereof.
Absstract of: MX2025001775A
Provided herein are antibodies, or fragments thereof, that specifically bind to a microtubule-binding region (MTBR) of tau, and uses thereof. Further provided are methods of detecting species of MTBR in blood or cerebral spinal fluid, and the use of such detection for diagnosing, prognosing, or staging pathological features and/or clinical symptoms of tauopathies, and to choose treatments appropriate for a given disease stage.
Absstract of: US2024294620A1
Provided herein are modified immunoglobulins comprising an amyloid reactive peptide joined to an antibody, as well as humanized antibodies that bind to human amyloid fibrils and antibody-peptide fusion proteins. Also provided herein are methods of treating amyloid-based diseases by administering a modified immunoglobulin, humanized antibody, or antibody-peptide fusion protein.
Absstract of: WO2024107948A1
A process for determining an extent of a central nervous system (CNS) specific neurological condition in a subject including collecting a biological sample of biofluid from the subject and measuring a quantity of a first biomarker, or metabolite of or mRNA corresponding to, the first biomarker from the sample from a dried spot or through a microfluidic device. The biofluid is capillary blood or saliva, which affords ease of collection advantages that are attractive for field-, hospital-, and home-based environments. The process being useful in the diagnosis, care, and management of brain specific abnormal neurological conditions in general, and in particular, to traumatic brain injury (TBI) and (TBI-induced) Alzheimer's disease (AD) and Alexander disease, in which a GFAP mutation is implicated in white matter deterioration.
Absstract of: TW202438878A
The present disclosure provides a method of manufacturing a biosensor for detecting a biomarker of Alzheimer's disease, comprising steps of depositing an aluminum oxide film on a Si substrate by an atomic layer deposition system to form an Al2O3/Si substrate; depositing electrical contacts Cr/Au on the Al2O3/Si substrate by a thermal evaporator to form a source, a drain and a planar gate on the Al2O3/Si substrate; providing a bilayer graphene on the Al2O3/Si substrate by thermal annealing under a vacuum environment; providing a bilayer graphene to a low-damage plasma treatment (LDPT) with a mixture of oxygen and hydrogen to form a graphene oxide/graphene (GO/G) layered composite on the Al2O3/Si substrate; and immobilizing an antibody on a surface of the GO/G layered composite through a reaction between amine groups of the antibody and carboxyl groups of GO of the GO/G layered composites, wherein the antibody is specific for p-tau217 protein.
Absstract of: WO2025188949A1
A sample collection device having a sample container, a solid phase binding material, and a container sealing component is presented. The sample container may have a housing that forms an opening for receiving a sample, and that encloses a space for holding the sample. The solid phase binding material may be disposed within the space enclosed by the housing of the sample container and may be adapted, when the sample contains an analyte, to bind specifically to the analyte. The container sealing component may be removably attachable to the sample container at the opening thereof, and may be adapted, when attached to the sample container, to form a seal around the opening of the sample container.
Absstract of: WO2025188889A1
This disclosure provides a method of sample processing, the method comprising (a) obtaining a sample from a subject having or suspected of having neurodegeneration, (b) determining an amount of one or more taxa in the sample, and (c) comparing the amount of the one or more taxa to a control amount. Also provided are methods of treating neurodegeneration.
Absstract of: US2025283897A1
Disclosed is a method for diagnosing Alzheimer's disease based on deep learning and an SAM, and a SERS substrate therefor. According to an embodiment, a deep learning and self-assembled monolayer (SAM)-based Alzheimer's disease diagnosing method performed by a computer device includes preparing a three-dimensional (3D) surface-enhanced Raman scattering (SERS) substrate by continuously stacking nanowire layers arranged in parallel by using a nanotransfer printing technology, forming an SAM on the 3D SERS substrate, and obtaining a Raman signal by applying a metabolite solution on the 3D SERS substrate having the SAM on a surface.
Absstract of: US2025283892A1
The present invention relates to a method for the diagnosis of Alzheimer's Disease, comprising the steps of (i) determining the level of antibodies against YB-1 in a sample from a subject to be diagnosed, (ii) comparing the determined level in the sample to a control level derived from subjects without Alzheimer's Disease, wherein a decreased level in the sample from the subject to be diagnosed as compared to the control level is indicative of Alzheimer's Disease in the subject.
Absstract of: WO2024097164A1
Provided are methods of phosho-tau aggregation-based biomarker discovery, and new utilities for discovered biomarkers in Alzheimer's disease (AD) diagnosis, differentiation, and treatment. Novel p-tau sites, p-tau198, p-tau396, and p-tau422, identified through such methods showed comparable or superior characteristics with established p-tau biomarkers, and identified biomarkers were capable of differentiating AD or mild cognitive impairment (MCI) from cognitively normal controls.
Absstract of: AU2023371615A1
Provided herein are biomarkers present in cell-free DNA (cfDNA) for the early detection of pre-clinical Alzheimer's Disease (AD), mild cognitive impairment (MCI), or AD in a subject. The detection of such biomarkers in a subject may be used to inform methods of treating a subject with a therapy (e.g., a drug or biologic) for pre-clinical Alzheimer's Disease (AD), mild cognitive impairment (MCI), or AD. The biomarkers disclosed herein may also be used in methods to monitor the progression of pre-clinical AD, MCI, or AD.
Absstract of: US2025277268A1
Embodiments of the present disclosure herein relate to a method for providing information for predicting a risk group for developing Alzheimer's disease dementia or a risk group for early onset of Alzheimer's symptoms, or a risk group for developing amnestic mild cognitive impairment and/or a positron emission tomography (PET)-positive risk group for amyloid β deposition, based on European population data. In an embodiment, the method makes it possible to accurately predict a risk group for developing Alzheimer's disease dementia or a risk group for early onset of Alzheimer's symptoms, or a risk group for developing amnestic mild cognitive impairment and/or a positron emission tomography (PET)-positive risk group for amyloid β deposition by using only at least 11 single-nucleotide polymorphisms, and the ability to predict the risk groups is further enhanced when up to and at most 39 additional single-nucleotide polymorphisms are used.
Absstract of: AU2025220690A1
A method for identifying pre-disposition to cognitive decline in a subject, the method comprising determining levels of: (a) omega-3 fatty acids, and vitamin D or a metabolite thereof; (b) omega-3 fatty acids, and homocysteine; (c) vitamin D or a metabolite thereof, and homocysteine; or (d) omega-3 fatty acids, vitamin D or a metabolite thereof, and 5 homocysteine, independently in one or more samples obtained from the subject. A method for identifying pre-disposition to cognitive decline in a subject, the method comprising determining levels of: (a) omega-3 fatty acids, and vitamin D or a metabolite thereof; (b) omega-3 fatty acids, and homocysteine; (c) vitamin D or a metabolite thereof, and 5 homocysteine; or (d) omega-3 fatty acids, vitamin D or a metabolite thereof, and homocysteine, independently in one or more samples obtained from the subject. ug m e t h o d f o r i d e n t i f y i n g p r e - d i s p o s i t i o n t o c o g n i t i v e d e c l i n e i n a s u b j e c t , t h e m e t h o d u g c o m p r i s i n g d e t e r m i n i n g l e v e l s o f : ( a ) o m e g a - f a t t y a c i d s , a n d v i t a m i n o r a m e t a b o l i t e t h e r e o f ; ( b ) o m e g a - f a t t y a c i d s , a n d h o m o c y s t e i n e ; ( c ) v i t a m i n o r a m e t a b o l i t e t h e r e o f , a n d h o m o c y s t e i n e ; o r ( d ) o m e g a - f a t t y a c i d s , v i t a m i n o r a m e t a b o l i t e t h e r e o f , a n d h o m o c y s t e i n e , i n d e p e n d e n t l
Absstract of: WO2025182761A1
Provided is a method for detecting GFAP in a sample by immunoassay, the method including a first step for forming a complex of a first antibody and GFAP, and a second step for forming a complex of a second antibody and GFAP, the first antibody binding to a region consisting of amino acids at positions 111 to 115 in the amino acid sequence of GFAP.
Absstract of: US2025277799A1
Provided herein are compositions and methods relating to improved assays for establishing Alzheimer's disease. Further provided herein are compositions and methods comprising improved antibodies for assays including immunoassays.
Absstract of: US2025277798A1
The invention relates to skin biomarkers, and in particular, to skin biomarkers for diagnosing and prognosing neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease, as well as diagnostic and prognostic methods and kits for these conditions. The invention also provides methods of treating neurodegenerative disorders. The invention further provides the use of biomarkers in the skin for skin aging (biological & chronological), and kits for detecting and quantifying skin aging, and also methods for treating, preventing or slowing down skin aging.
Absstract of: WO2025181335A1
The invention pertains to treating a cognitive impairment, for example, an aging-associated cognitive impairment. In certain aspects, a sample obtained from a subject is assayed for the ratio between the levels of any two proteins selected from: DLL1, SMOC1, CD59, TSTD1, STAT3, POLD4, PARP11, LEFTY2, UNC5B, C5, C5.C6, ASH2L, INHBB, RSP3, VAV3, SIRT3 and SERPINB8. A subject may be having or suspected of having a cognitive impairment. The cognitive impairment can be caused by a neurodegenerative disease, such as Alzheimer's disease. A subject may be identified as likely or not likely to respond positively to the plasma exchange therapy based on the ratio between the levels of measured proteins. In certain aspects, methods for treating a cognitive impairment in the subject comprise administering a plasma exchange therapy comprising a full and/or low volume plasma exchange. Also provided are kits suitable for performing such methods.
Absstract of: NZ746574A
The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
Absstract of: KR20250129282A
본 발명은 루이소체병의 증상을 동반한 알츠하이머병 환자를 정상대조군과 구분하여 진단할 수 있는 영상 바이오 마커에 관한 것으로, 보다 상세하게는, 본 발명은 중뇌 흑색질의 도파민 운반체 섭취율(DAT-SN), 및 선조체 조가비핵의 조기 도파민 섭취율 대 지연 도파민 섭취율의 비율(E/D-PP)을 영상 바이오마커로 사용하여 정상대조군과 구별하여 루이소체병의 증상을 동반한 알츠하이머병 환자의 진단 정확도를 높이는 효과를 제공한다.
Absstract of: JP2024147610A
To provide antibodies for use in the treatment of neurodegenerative diseases, or pharmaceutical compositions thereof.SOLUTION: The present invention provides compounds and methods targeting human tau, particularly human tau phosphorylated at threonine (217) and isoforms of tau expressed only in the CNS, including therapeutic antibodies, pharmaceutical compositions and diagnostic applications useful in the field of neurodegenerative diseases such as AD, PSP and FTD.SELECTED DRAWING: None
Absstract of: US2025268982A1
Non-aggregating protein analogues of proteins involved in a proteinopathy, for example Alzheimer's disease, are provided. The protein has a beta-sheet aggregation domain, and the non-aggregating protein analogue has a beta-sheet destabilizing modification in the beta-sheet aggregation domain but substantially retains wild type protein function. The beta-sheet destabilizing modification can be a substitution of a naturally occurring amino acid for a non-naturally occurring amino acid. Methods of treating a proteinopathy using the non-aggregating protein analogues and methods of designing a non-aggregating protein analogue are provided.
Absstract of: US2025270301A1
The invention relates to isolated recombinant peptides comprising an epitope from human tau 2N4R. The invention also relates to antibodies, specific for isolated recombinant peptides comprising an epitope from human tau 2N4R and to such antibodies for use in investigation, diagnosis and treatment of tauopathies, such as Alzheimer's disease.
Absstract of: WO2025179300A1
Methods, compositions, and kits are capable of detecting, identifying, diagnosing, prognosing, assessing, monitoring, and/or treating a neurological injury such as acute TBI and distinguishing geriatric TBI from conditions such as dementia, Alzheimer's Disease, Parkinson's disease and the like. Also disclosed are methods of testing elderly patients who have or are suspected of having traumatic brain injury using panels of biomarkers that distinguish TBI from dementia, and, optionally, treating such patients for TBI or dementia based upon the results of the biomarker tests.
Absstract of: US2025271453A1
A protein antigen combination containing SERF2 and applications thereof in the field of biological detection are disclosed. The antigen combination for detecting autoantibodies can distinguish Alzheimer's disease (AD) from frontotemporal dementia (FTD) and dementia with Lewy bodies (DLB), and the antigen combination at least includes protein fragments of SERF2. The new protein antigen composition can not only effectively identify patients with AD, but also effectively distinguish AD from FTD and DLB, enabling accurate identification of AD. It is of great importance in terms of diagnostic applications and research.
Nº publicación: US2025270618A1 28/08/2025
Applicant:
THE CHILDRENS MEDICAL CENTER CORP [US]
The Children's Medical Center Corporation
Absstract of: US2025270618A1
Provided herein are methods for diagnosing and treating Alzheimer's disease in a subject comprising determining the expression level of three, four or five members of a panel of proteins in a biological sample obtained from the subject.
BOPI
Electronic site
